J&J declares new data from Phase III trial of icotrokinra for plaque psoriasis

Johnson & Johnson (J&J) reported new data from the Phase III ICONIC-TOTAL trial evaluating icotrokinra, an oral peptide, for treating plaque psoriasis (PsO). The trial, involving 311 subjects aged 12 and above with moderate PsO, compared icotrokinra to a placebo. The primary endpoint was met, with 57% of treated subjects achieving clear or almost clear skin at week 16, compared to 6% in the placebo group. High skin clearance rates were seen in subjects with scalp (66%) and genital (77%) psoriasis. In hand/foot psoriasis, 42% of treated subjects showed significant improvement. The therapy’s safety profile was favorable with no safety signals observed.

Icotrokinra selectively blocks the IL-23 receptor, key in PsO’s inflammatory response. This study is part of J&J's larger ICONIC development program, which aims to shift treatment paradigms in moderate-to-severe plaque psoriasis.

12-05-2025